These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19890998)

  • 41. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
    McIntyre RS; Konarski JZ; Jones M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study.
    Cookson J; Keck PE; Ketter TA; Macfadden W
    Int Clin Psychopharmacol; 2007 Mar; 22(2):93-100. PubMed ID: 17293709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Depressive symptoms and the Idiopathic Parkinson's Syndrome (IPS): a review].
    Giupponi G; Pycha R; Erfurth A; Hausmann A; Conca A
    Neuropsychiatr; 2008; 22(2):71-82. PubMed ID: 18606109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease: a preliminary study of yohimbine challenge in patients with anxiety.
    Richard IH; Szegethy E; Lichter D; Schiffer RB; Kurlan R
    Clin Neuropharmacol; 1999; 22(3):172-5. PubMed ID: 10367182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversible withdrawal dyskinesia associated with quetiapine.
    Michaelides C; Thakore-James M; Durso R
    Mov Disord; 2005 Jun; 20(6):769-70. PubMed ID: 15747370
    [No Abstract]   [Full Text] [Related]  

  • 47. [Risk of QTc prolongation due to combination of ziprasidone and quetiapine].
    Minov C
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S142-4. PubMed ID: 15570533
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).
    Vieta E; Suppes T; Eggens I; Persson I; Paulsson B; Brecher M
    J Affect Disord; 2008 Aug; 109(3):251-63. PubMed ID: 18579216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.
    Prohorov T; Klein C; Miniovitz A; Dobronevsky E; Rabey JM
    J Neurol; 2006 Feb; 253(2):171-5. PubMed ID: 16096815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe urinary retention requiring urinary catheterization associated with combined treatment of depression with duloxetine and quetiapine.
    Wang SM; Lee KU; Jeon YW; Park EJ; Han SI
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):191. PubMed ID: 23581874
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease.
    Mancini F; Tassorelli C; Martignoni E; Moglia A; Nappi G; Cristina S; Pacchetti C
    Clin Neuropharmacol; 2004; 27(1):33-7. PubMed ID: 15090935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quetiapine and falsely elevated nortriptyline level.
    Schussler JM; Juenke JM; Schussler I
    Am J Psychiatry; 2003 Mar; 160(3):589. PubMed ID: 12611850
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA panel issues mixed decision on quetiapine in depression and anxiety.
    Kuehn BM
    JAMA; 2009 May; 301(20):2081-2. PubMed ID: 19470978
    [No Abstract]   [Full Text] [Related]  

  • 54. Novel approach to managing severely labile blood pressure during maintenance electroconvulsive therapy in a man with psychotic depression and Parkinson disease.
    Bortolotti A; MacPherson R; Subau D
    J ECT; 2012 Jun; 28(2):e11. PubMed ID: 22622295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Role of dopamine receptor agonists in the treatment of depression in patients with Parkinson's disease].
    Fedorova NV; Miretskaia AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(12):87-92. PubMed ID: 20178161
    [No Abstract]   [Full Text] [Related]  

  • 56. Capgras delusion for animals and inanimate objects in Parkinson's Disease: a case report.
    Islam L; Piacentini S; Soliveri P; Scarone S; Gambini O
    BMC Psychiatry; 2015 Apr; 15():73. PubMed ID: 25886646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacotherapy in Bipolar Depression Comorbid With Parkinson's Disease: A Case Report.
    Wang JK; Lee HC
    J Neuropsychiatry Clin Neurosci; 2015; 27(3):e213. PubMed ID: 26222973
    [No Abstract]   [Full Text] [Related]  

  • 58. A possible case of peduncular hallucinosis in a patient with Parkinson's disease successfully treated with quetiapine.
    Spiegel DR; Lybeck B; Angeles V
    J Neuropsychiatry Clin Neurosci; 2009; 21(2):225-6. PubMed ID: 19622697
    [No Abstract]   [Full Text] [Related]  

  • 59. Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in Parkinson's disease.
    Marino L; Friedman JH
    Int J Neurosci; 2013 Jan; 123(1):70-1. PubMed ID: 23038993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of punding in Parkinson's disease: an open-label prospective study.
    Fasano A; Ricciardi L; Pettorruso M; Bentivoglio AR
    J Neurol; 2011 Apr; 258(4):656-60. PubMed ID: 21072531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.